{
  "id": "fda_guidance_chunk_0724",
  "title": "Introduction - Part 724",
  "text": "OF CONTENTS I. INTRODUCTION (1.0)............................................................................................................................................1 A. GENERAL SCHEME AND PURPOSE OF GUIDANCE (1.1) .........................................................................................2 B. PURPOSE OF CONTROL GROUP (1.2) ......................................................................................................................3 1. Randomization (1.2.1).......................................................................................................................................3 2. Blinding (1.2.2)..................................................................................................................................................4 C. TYPES OF CONTROLS (1.3) .....................................................................................................................................4 1. Placebo Concurrent Control (1.3.1)................................................................................................................5 2. No-treatment Concurrent Control (1.3.2) .......................................................................................................5 3. Dose-response Concurrent Control (1.3.3).....................................................................................................5 4. Active (Positive) Concurrent Control (1.3.4)..................................................................................................6 5. External Control (Including Historical Control) (1.3.5)................................................................................6 6. Multiple Control Groups (1.3.6)......................................................................................................................6 D. PURPOSES OF CLINICAL TRIALS AND RELATED ISSUES (1.4) ...............................................................................6 1. Evidence of Efficacy (1.4.1)..............................................................................................................................7 2. Comparative Efficacy and Safety (1.4.2).........................................................................................................7 3. Fairness of Comparisons (1.4.3)......................................................................................................................7 a. Dose (1.4.3.1) ....................................................................................................................................................... 8 b. Patient Population (1.4.3.2) ................................................................................................................................... 8 c. Selection and Timing of Endpoints (1.4.3.3) .......................................................................................................... 8 E. ASSAY SENSITIVITY (1.5).......................................................................................................................................9 1. Assay Sensitivity in Non-inferiority or Equivalence Trials (1.5.1)...............................................................9 a. Historical Evidence of Sensitivity to Drugs Effects and Choosing the Non-inferiority Margin (1.5.1.1) ................. 10 b. Appropriate Trial Conduct (1.5.1.2)..................................................................................................................... 12 2. Assay Sensitivity in Trials Intended to Demonstrate Superiority (1.5.2) ................................................... 13 II. DETAILED CONSIDERATION OF TYPES OF CONTROL (2.0)............................................................. 14 A. PLACEBO CONTROL (2.1) .................................................................................................................................... 14 1. Description (See Section 1.3.1) (2.1.1)......................................................................................................... 14 2. Ability to Minimize Bias (2.1.2) .................................................................................................................... 14 3. Ethical Issues (2.1.3)...................................................................................................................................... 14 4. Usefulness of Placebo-controlled Trials and Validity of Inference in Particular Situations (2.1.4) ....... 15 5. Modifications of Design and Combinations with Other Controls That Can Resolve Ethical, Practical, or Inferential Issues (2.1.5).......................................................................................................................................... 16 a. Additional Control Groups (2.1.5.1) .................................................................................................................... 16 b. Other Modifications of Study Design (2.1.5.2) ..................................................................................................... 17 6. Advantages of Placebo-controlled Trials (2.1.6)......................................................................................... 19 a. Ability to Demonstrate Efficacy (2.1.6.1) ........................................................................................................... 19 b. Measures Absolute Efficacy and Safety (2.1.6.2).................................................................................................. 19 c. Efficiency (2.1.6.3) ............................................................................................................................................. 19 d. Minimizing the Effect of Subject and Investigator Expectations (2.1.6.4).............................................................. 20 7. Disadvantages of Placebo-controlled Trials (2.1.7).................................................................................... 20 a. Ethical Concerns (See Sections 2.1.3 and 2.1.4) (2.1.7.1) ..................................................................................... 20 b. Patient and Physician Practical Concerns (2.1.7.2) ............................................................................................... 20 c. Generalizability (2.1.7.3) .................................................................................................................................... 20 d. No Comparative Information (2.1.7.4) ................................................................................................................. 21 B. NO-TREATMENT CONCURRENT CONTROL (SEE SECTION 1.3.2) (2.2) ............................................................ 21 C. DOSE-RESPONSE CONCURRENT CONTROL (SEE SECTION 1.3.3) (2.3) ............................................................ 21 1. Description (2.3.1)......................................................................................................................................... 21 2. Ability to Minimize Bias (2.3.2) .................................................................................................................... 22 3. Ethical Issues (2.3.3)...................................................................................................................................... 22 4. Usefulness of Dose-response Studies and Validity of Inference in Particular Situations (2.3.4)............. 22 5. Modifications of Design and Combinations with Other Controls That",
  "source": "FDA_clinical_trial_guidance.txt",
  "section_heading": "Introduction",
  "start_pos": 971712,
  "end_pos": 973248,
  "tokens": 512,
  "tags": [
    "safety",
    "efficacy",
    "design",
    "regulatory",
    "clinical_trial"
  ],
  "jurisdiction": "US",
  "document_type": "fda_guidance",
  "guidance_section": "general_guidance",
  "regulatory_weight": "mandatory",
  "created_at": "2025-10-23T02:25:44.734Z"
}